Clinical Trial Update: Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase Ib/II trial evaluating interleukin-2 in combination with nivolumab for metastatic clear cell renal cell carcinoma; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-09